Alphatec Holdings vs Tandem Diabetes Care
Tandem Diabetes Care is the larger business, with $1.01bn of revenue in fiscal 2025 against $764m for Alphatec Holdings (1.3 times as much). Alphatec Holdings grew faster (25.0% against 7.9%). Alphatec Holdings kept more of each dollar of sales as profit: a net margin of -18.8% against -20.2%. Tandem Diabetes Care carries less debt relative to equity (199.8% against 5566.3%).
| Latest fiscal year | Alphatec HoldingsATEC, 2025 | Tandem Diabetes CareTNDM, 2025 |
|---|---|---|
| Revenue | $764m | $1.01bn |
| Revenue growth | 25.0% | 7.9% |
| Net income | −$143m | −$205m |
| Operating margin | -10.7% | -18.5% |
| Net margin | -18.8% | -20.2% |
| Return on equity | — | -97.9% |
| Free cash flow | $2.8m | −$29.7m |
| Cash | $161m | $90.6m |
| Total debt | $692m | $310m |
| Debt to equity | 5566.3% | 199.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | 913 | 2,500 |
| Market value | $1.17bn | $1.23bn |
| Price vs our value range | — | — |
| Moat score | 28 (Weak) | 30 (Weak) |
| Insider trades, 12 months | 5 buys, 41 sales | 0 buys, 3 sales |